{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-078328","form_type":"8-K","ticker":"LABT","cik":"0002079272","company_name":"Lakewood-Amedex Biotherapeutics Inc.","filed_at":"2026-07-15T20:15:21+00:00","discovered_at":"2026-07-15T20:17:00.482963+00:00","generated_at":"2026-07-15T20:17:14.333336+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"medium","headline":"Lakewood-Amedex releases investor deck on Bisphosphocin platform and Nu-3 gel for diabetic foot ulcers","bullets":["Investor deck highlights Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials.","Lead program Nu-3 is a topically delivered antimicrobial gel for infected diabetic foot ulcers (iDFU).","Deck includes preclinical/clinical data, regulatory strategy, intellectual property, and competitive landscape.","Presentation is for use in meetings with investors, analysts, and third parties; no material financial updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-078328","json":"https://secwatch.observer/filing/0001213900-26-078328.json","markdown":"https://secwatch.observer/filing/0001213900-26-078328.md","text":"https://secwatch.observer/filing/0001213900-26-078328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/0001213900-26-078328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/ea0297963-8k_lakewood.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T20:17:14.333336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}